Video

Dr. Garassino on Updates From the KEYNOTE-189 Trial in NSCLC

Marina Chiara Garassino, MD, discusses updates from the phase 3 KEYNOTE-189 trial in non–small cell lung cancer.

Marina Chiara Garassino, MD, professor of Medicine, Hematology and Oncology, The University of Chicago Department of Medicine, discusses updates from the phase 3 KEYNOTE-189 (NCT02578680) trial in non–small cell lung cancer (NSCLC).

KEYNOTE-189 evaluated pembrolizumab (Keytruda) plus pemetrexed/platinum-based chemotherapy vs pemetrexed/platinum-based chemotherapy alone in previously untreated patients with metastatic NSCLC.

Data presented at the 2022 ESMO Congress showed that at 5 years of follow-up, patients who completed 35 cycles of pembrolizumab plus chemotherapy over the course of 2 years experienced durable responses, with 72% of those patients still alive 3 years following the end of treatment, Garassino explains.

The combination was also well tolerated, and investigators did not observe any surprising adverse effects, adding to the feasibility of a 2-year treatment duration, Garassino concludes.

Related Videos
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS